Merz Partners with SAFE to Launch New Patient-Centric Spasticity Initiative
Merz Pharmaceuticals has announced the launch of Life With Spasticity , an educational online platform intended to provide comprehensive information and motivational support for stroke survivors who experience post-stroke spasticity. Designed by and for individuals living with spasticity, the project is funded by Merz and has been developed in partnership with Stroke Alliance For Europe (SAFE) .
“In addition to providing emotional support and motivation for stroke survivors, the ‘Life With Spasticity’ website also offers a meaningful overview of post-stroke spasticity treatments and rehabilitation processes. We want to ensure that stroke survivors and their caregivers receive accurate and accessible information about the treatment options available to them,” said Jon Barrick, the President of SAFE. “We believe that everyone who has had a stroke should have the opportunity to make the best possible recovery.”
It is estimated that spasticity affects up to a third of stroke survivors and can leave those with the condition dependent on others to carry out the most basic, everyday tasks, such as getting dressed and eating. Studies have shown that around 70% of stroke survivors living with spasticity report that it has a major impact on their life.
“Merz continues to seek out and incorporate direct patient input for our ongoing spasticity and post-stroke awareness initiatives, which we believe should be shaped according to patients’ real needs from the very beginning,” explained Dr. Yannick Grosskreutz, Executive Director and Head of Global Marketing Neurotoxins for Merz Pharmaceuticals. “The ‘Life With Spasticity’ website is just one example of how we are putting that concept into practice.”
To bring this initiative to life, Merz partnered with a patient advisory board of European stroke survivors and carers living with spasticity, as well as SAFE board members, to test and refine the “Life With Spasticity” website prior to launch. Patient advisory board feedback was incorporated to improve the site’s overall accessibility and to generate content for the FAQs section.
“In my experience as a stroke survivor even mild spasticity can be a huge problem. It affects your quality of life; it is uncomfortable and painful. Yet, the problem is not widely recognized by doctors and patients. It is impossible to fight an unknown enemy, and that is why I'm very happy to be a part of this project, which provides reliable information about spasticity. I'm sure that this project will help a number of people who struggle with neurological problems,” stated patient ambassador Kasia Siewruk.
In the coming months, Merz will continue to work closely with SAFE and with patient ambassadors to regularly update the FAQs section of the Life With Spasticity website so that the patients, families and carers can deepen their understanding of post-stroke spasticity, share experiences and find support in their daily life activities.
For more information on Merz Pharma Group, please click on www.merz.com .
For more information on Stroke Alliance For Europe: www.safestroke.eu .
Mariana Smith Bourland
Phone: +49 151 4249 1466.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum